Hypoxanthine—early biomarker of outcomes in an ovine model of neonatal hypoxic ischemic encephalopathy

Our study identified plasma hypoxanthine as an early biomarker for hypoxic-ischemic encephalopathy (HIE) in an ovine model and uncovered a novel correlation between hypoxanthine levels and the severity of neurologic impairment in asphyxiated lambs. These findings highlight the potential of metabolomics in the early detection of HIE, paving the way for improved diagnostic and prognostic strategies. Translating these insights into clinical practice could enable the development of predictive tools for outcome assessment and resource allocation, ultimately enhancing early intervention and optimizing care for neonates at risk of HIE.